Christian Sticherling

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1642829/publications.pdf

Version: 2024-02-01

260 papers

13,982 citations

48 h-index

44042

24232 110 g-index

271 all docs

271 docs citations

271 times ranked

11411 citing authors

#	Article	IF	CITATIONS
1	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 2021, 42, 373-498.	1.0	5,583
2	2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). European Heart Journal, 2020, 41, 655-720.	1.0	647
3	Electrical storm in patients with transvenous implantable cardioverter-defibrillators. Journal of the American College of Cardiology, 1998, 32, 1909-1915.	1.2	345
4	Diagnostic value of tachycardia features and pacing maneuvers during paroxysmal supraventricular tachycardia. Journal of the American College of Cardiology, 2000, 36, 574-582.	1.2	327
5	Induction of Cytokine Expression in Leukocytes by Binding of Thrombin-Stimulated Platelets. Circulation, 1997, 95, 2387-2394.	1.6	309
6	Cryoballoon or radiofrequency ablation for symptomatic paroxysmal atrial fibrillation: reintervention, rehospitalization, and quality-of-life outcomes in the FIRE AND ICE trial. European Heart Journal, 2016, 37, 2858-2865.	1.0	272
7	Differentiation of atypical atrioventricular node re-entrant tachycardia from orthodromic reciprocating tachycardia using a septal accessory pathway by the response to ventricular pacing. Journal of the American College of Cardiology, 2001, 38, $1163-1167$.	1.2	245
8	Arrhythmias in congenital heart disease: a position paper of the European Heart Rhythm Association (EHRA), Association for European Paediatric and Congenital Cardiology (AEPC), and the European Society of Cardiology (ESC) Working Group on Grown-up Congenital heart disease, endorsed by HRS, PACES, APHRS, and SOLAECE. Europace, 2018, 20, 1719-1753.	0.7	210
9	Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación CardÃaca y ElectrofisiologÃa (SOLAECE). Europace, 2017, 19, 1589-1623.	0.7	208
10	Device-detected subclinical atrial tachyarrhythmias: definition, implications and management—an European Heart Rhythm Association (EHRA) consensus document, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación CardÃaca y ElectrofisiologÃa (SOLEACE). Europace, 2017, 19, 1556-1578.	0.7	186
11	Pre-participation cardiovascular evaluation for athletic participants to prevent sudden death: Position paper from the EHRA and the EACPR, branches of the ESC. Endorsed by APHRS, HRS, and SOLAECE. European Journal of Preventive Cardiology, 2017, 24, 41-69.	0.8	181
12	Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRS). Europace, 2015, 17, 1197-1214.	0.7	160
13	Relationships of Overt and Silent Brain Lesions With Cognitive Function in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2019, 73, 989-999.	1.2	148
14	Double potentials along the ablation line as a guide to radiofrequency ablation of typical atrial flutter. Journal of the American College of Cardiology, 2001, 38, 750-755.	1.2	147
15	Antiarrhythmic drugsa Clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP).	0.7	144
16	Necessity for Surgical Revision of Defibrillator Leads Implanted Long-Term. Circulation, 2008, 117, 2727-2733.	1.6	135
17	Death Without Prior Appropriate Implantable Cardioverter-Defibrillator Therapy. Circulation, 2008, 117, 1918-1926.	1.6	121
18	Repeat Ablation for Atrial Fibrillation Recurrence Post Cryoballoon or Radiofrequency Ablation in the FIRE AND ICE Trial. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e007247.	2.1	116

#	Article	IF	CITATIONS
19	Cryoballoon versus radiofrequency catheter ablation of paroxysmal atrial fibrillation: Biomarkers of myocardial injury, recurrence rates, and pulmonary vein reconnection patterns. Heart Rhythm, 2010, 7, 1770-1776. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus	0.3	115
20	Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de	0.7	107
21	Estimulaci \tilde{A}^3 n Card \tilde{A} aca y. Europace, 2017, 19, 1757-1758. Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. Europace, 2014, 16, 1655-1673.	0.7	105
22	Prevalence of central venous occlusion in patients with chronic defibrillator leads. American Heart Journal, 2001, 141, 813-816.	1.2	101
23	Complete atrioventricular block after valvular heart surgery and the timing of pacemaker implantation. American Journal of Cardiology, 2001, 87, 649-651.	0.7	93
24	Initial impedance decrease as an indicator of good catheter contact: Insights from radiofrequency ablation with force sensing catheters. Heart Rhythm, 2014, 11, 194-201.	0.3	92
25	Trypanosoma bruceitryparedoxin, a thioredoxin-like protein in African trypanosomes. FEBS Letters, 1998, 431, 381-385.	1.3	89
26	Right Atrial Pacing Impairs Cardiac Function During Resynchronization Therapy. Journal of the American College of Cardiology, 2005, 45, 1482-1487.	1.2	88
27	Pre-participation cardiovascular evaluation for athletic participants to prevent sudden death: Position paper from the EHRA and the EACPR, branches of the ESC. Endorsed by APHRS, HRS, and SOLAECE. Europace, 2017, 19, euw243.	0.7	86
28	Impact of Female Sex on Clinical Outcomes in the FIRE AND ICE Trial of Catheter Ablation for Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e006204.	2.1	78
29	Clinical effectiveness of primary prevention implantable cardioverter-defibrillators: results of the EU-CERT-ICD controlled multicentre cohort study. European Heart Journal, 2020, 41, 3437-3447.	1.0	78
30	Brugada Syndrome Mimicked by Tricyclic Antidepressant Overdose. Journal of Cardiovascular Electrophysiology, 2001, 12, 275-275.	0.8	77
31	The prognosis of implantable defibrillator patients treated with cardiac resynchronization therapy: comorbidity burden as predictor of mortality. Europace, 2011, 13, 62-69.	0.7	77
32	European Heart Rhythm Association (EHRA) consensus document on management of arrhythmias and cardiac electronic devices in the critically ill and post-surgery patient, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin American Heart Rhythm Society (LAHRS). Europace, 2019, 21, 7-8.	0.7	72
33	Amiodarone-Induced Thyrotoxicosis. Journal of the American College of Cardiology, 2007, 49, 2350-2355.	1.2	71
34	Anatomical Predictors for Acute and Midâ€√erm Success of Cryoballoon Ablation of Atrial Fibrillation Using the 28 mm Balloon. Journal of Cardiovascular Electrophysiology, 2013, 24, 132-138.	0.8	69
35	Transient bilateral cortical blindness after coronary angiography. Lancet, The, 1998, 351, 570.	6.3	65
36	The wearable cardioverter-defibrillator: current technology and evolving indications. Europace, 2017, 19, 335-345.	0.7	65

#	Article	IF	Citations
37	Role of Transisthmus Conduction Intervals in Predicting Bidirectional Block after Ablation of Typical Atrial Flutter. Journal of Cardiovascular Electrophysiology, 2001, 12, 169-174.	0.8	62
38	Effects of Digoxin on Acute, Atrial Fibrillation–Induced Changes in Atrial Refractoriness. Circulation, 2000, 102, 2503-2508.	1.6	61
39	Cardiac arrhythmias in the emergency settings of acute coronary syndrome and revascularization: an European Heart Rhythm Association (EHRA) consensus document, endorsed by the European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Acute Cardiovascular Care Association (ACCA), Europace, 2019, 21, 1603-1604.	0.7	61
40	Longevity of implantable cardioverter-defibrillators, influencing factors, and comparison to industry-projected longevity. Heart Rhythm, 2009, 6, 1737-1743.	0.3	58
41	2019 APHRS expert consensus statement on threeâ€dimensional mapping systems for tachycardia developed in collaboration with HRS, EHRA, and LAHRS. Journal of Arrhythmia, 2020, 36, 215-270.	0.5	57
42	Electrogram Polarity and Cavotricuspid Isthmus Block During Ablation of Typical Atrial Flutter. Journal of Cardiovascular Electrophysiology, 2001, 12, 393-399.	0.8	56
43	Sex differences in outcomes of primary prevention implantable cardioverter-defibrillator therapy: combined registry data from eleven European countries. Europace, 2018, 20, 963-970.	0.7	54
44	Effect of Chronic Amiodarone Therapy on Defibrillation Energy Requirements in Humans. Journal of Cardiovascular Electrophysiology, 2000, 11, 736-740.	0.8	52
45	Validation of a novel spiral mapping catheter for real-time recordings from the pulmonary veins during cryoballoon ablation of atrial fibrillation. Heart Rhythm, 2013, 10, 241-246.	0.3	50
46	Occupational radiation exposure in the electrophysiology laboratory with a focus on personnel with reproductive potential and during pregnancy: A European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS). Europace, 2017, 19, 1909-1922.	0.7	50
47	Silent brain infarcts impact on cognitive function in atrial fibrillation. European Heart Journal, 2022, 43, 2127-2135.	1.0	50
48	Methadone-induced Torsade de pointes tachycardias. Swiss Medical Weekly, 2005, 135, 282-5.	0.8	50
49	Cost-consequence analysis of daily continuous remote monitoring of implantable cardiac defibrillator and resynchronization devices in the UK. Europace, 2013, 15, 1601-1608.	0.7	49
50	Prediction of mortality benefit based on periodic repolarisation dynamics in patients undergoing prophylactic implantation of a defibrillator: a prospective, controlled, multicentre cohort study. Lancet, The, 2019, 394, 1344-1351.	6.3	49
51	Comparison of a Novel, Single-Lead Atrial Sensing System With a Dual-Chamber Implantable Cardioverter-Defibrillator System in Patients Without Antibradycardia Pacing Indications. Circulation: Arrhythmia and Electrophysiology, 2011, 4, 56-63.	2.1	47
52	Design of the Swiss Atrial Fibrillation Cohort Study (Swiss-AF): structural brain damage and cognitive decline among patients with atrial fibrillation. Swiss Medical Weekly, 2017, 147, w14467.	0.8	46
53	Incidence of new-onset atrial fibrillation after cavotricuspid isthmus ablation for atrial flutter. Europace, 2017, 19, 1776-1780.	0.7	45
54	Prospective Assessment of Sexâ€Related Differences in Symptom Status and Health Perception Among Patients With Atrial Fibrillation. Journal of the American Heart Association, 2017, 6, .	1.6	44

#	Article	IF	CITATIONS
55	Upgrades from a previous device compared to <i>de novo</i> cardiac resynchronization therapy in the European Society of Cardiology CRT Survey II. European Journal of Heart Failure, 2018, 20, 1457-1468.	2.9	44
56	Longevity of implantable cardioverter defibrillators: a comparison among manufacturers and over time. Europace, 2016, 18, 710-717.	0.7	41
57	Incidence and Predictors of Atrial Fibrillation Progression. Journal of the American Heart Association, 2019, 8, e012554.	1.6	41
58	Phrenic nerve palsy during ablation of atrial fibrillation using a 28-mm cryoballoon catheter: predictors and prevention. Journal of Interventional Cardiac Electrophysiology, 2013, 36, 47-54.	0.6	38
59	Heart Rate Variability Triangular Index as a Predictor of Cardiovascular Mortality in Patients With Atrial Fibrillation. Journal of the American Heart Association, 2020, 9, e016075.	1.6	38
60	An Electrocardiogram-Based Algorithm To Detect Loss of Left Ventricular Capture during Cardiac Resynchronization Therapy. Annals of Internal Medicine, 2005, 142, 968.	2.0	37
61	Pacemaker Implantation and Need for Ventricular Pacing during Followâ€Up after Transcatheter Aortic Valve Implantation. PACE - Pacing and Clinical Electrophysiology, 2014, 37, 1592-1601.	0.5	37
62	Long-term comparison of cryoballoon and radiofrequency ablation of paroxysmal atrial fibrillation: A propensity score matched analysis. International Journal of Cardiology, 2014, 176, 645-650.	0.8	37
63	Close connection between improvement in left ventricular function by cardiac resynchronization therapy and the incidence of arrhythmias in cardiac resynchronization therapyâ€defibrillator patients. European Journal of Heart Failure, 2010, 12, 1325-1332.	2.9	35
64	Out-of-hospital cardiac arrest due to idiopathic ventricular fibrillation in patients with normal electrocardiograms: results from a multicentre long-term registry. Europace, 2019, 21, 1670-1677.	0.7	34
65	Clinical impact of screening for sleep related breathing disorders in atrial fibrillation. International Journal of Cardiology, 2012, 154, 256-258.	0.8	31
66	Evaluation of the need of elective implantable cardioverter-defibrillator generator replacement in primary prevention patients without prior appropriate ICD therapy. Heart, 2014, 100, 1188-1192.	1.2	31
67	Intracardiac QRS Electrogram Width-An Arrhythmia Detection Feature for Implantable Cardioverter Defibrillators: Exercise Induced Variation as a Base for Device Programming. PACE - Pacing and Clinical Electrophysiology, 1998, 21, 1609-1617.	0.5	30
68	Contact force and impedance decrease during ablation depends on catheter location and orientation: insights from pulmonary vein isolation using a contact force-sensing catheter. Journal of Interventional Cardiac Electrophysiology, 2015, 43, 297-306.	0.6	30
69	Usefulness of Genetic Testing in Sudden Cardiac Arrest Survivors With or Without Previous Clinical Evidence of Heart Disease. American Journal of Cardiology, 2019, 123, 2031-2038.	0.7	30
70	Health-related quality of life in patients with atrial fibrillation: The role of symptoms, comorbidities, and the type of atrial fibrillation. PLoS ONE, 2019, 14, e0226730.	1.1	30
71	Fluctuation of left ventricular thresholds and required safety margin for left ventricular pacing with cardiac resynchronization therapy. Europace, 2009, 11, 931-936.	0.7	29
72	Role of Defibrillation Threshold Testing in the Contemporary Defibrillator Patient Population. Journal of Cardiovascular Electrophysiology, 2013, 24, 437-441.	0.8	29

#	Article	IF	CITATIONS
73	Effects of Sinus Rhythm Maintenance on Left Heart Function After Electrical Cardioversion of Atrial Fibrillation: Implications for Tachycardia-Induced Cardiomyopathy. Canadian Journal of Cardiology, 2015, 31, 36-43.	0.8	28
74	Crystallization and preliminary crystallographic analysis of trypanothione reductase from Trypanosoma cruzi, the causative agent of Chagas' disease. FEBS Letters, 1993, 317, 105-108.	1.3	27
75	Gender and age differences in induced atrial fibrillation. American Journal of Cardiology, 2001, 88, 436-438.	0.7	27
76	Introduction of new industry standards for cardiac implantable electronic devices: balancing benefits and unexpected risks. Europace, 2012, 14, 1081-1086.	0.7	27
77	Effect of Atrial Fibrillation Duration on Probability of Immediate Recurrence after Transthoracic Cardioversion. Journal of Cardiovascular Electrophysiology, 2003, 14, 182-185.	0.8	26
78	Changes in Implantation Patterns and Therapy Rates of Implantable Cardioverter Defibrillators over Time in Ischemic and Dilated Cardiomyopathy Patients. PACE - Pacing and Clinical Electrophysiology, 2016, 39, 848-857.	0.5	26
79	Left atrial anatomy, atrial fibrillation burden, and P-wave duration—relationships and predictors for single-procedure success after pulmonary vein isolation. Europace, 2018, 20, 271-278.	0.7	26
80	Gender Differences in Appropriate Shocks and Mortality among Patients with Primary Prophylactic Implantable Cardioverter-Defibrillators: Systematic Review and Meta-Analysis. PLoS ONE, 2016, 11, e0162756.	1.1	26
81	Incidence of and predictors for appropriate implantable cardioverter-defibrillator therapy in patients with a secondary preventive implantable cardioverter-defibrillator indication. Europace, 2016, 18, 227-231.	0.7	25
82	Worldwide Clinical Experience with aDown-Sized Active Can ImplantableCardioverier Defibrillator in 162 ConsecutivePatients. PACE - Pacing and Clinical Electrophysiology, 1998, 21, 1778-1783.	0.5	24
83	Holter monitoring for syncope: diagnostic yield in different patient groups and impact on device implantation. QJM - Monthly Journal of the Association of Physicians, 2007, 100, 771-777.	0.2	24
84	Electrophysiology Testing to Stratify Patients With Left Bundle Branch Block After Transcatheter Aortic Valve Implantation. Journal of the American Heart Association, 2020, 9, e014446.	1.6	23
85	First worldwide clinical experience with a new dual chamber implantable cardioverter defibrillator. Advantages and complications. Europace, 1999, 1, 96-102.	0.7	22
86	Value of VDD-pacing systems in patients with atrioventricular block: Experience over a decade. International Journal of Cardiology, 2007, 122, 239-243.	0.8	21
87	Performance of the Seattle Heart Failure Model in Implantable Defibrillator Patients Treated With Cardiac Resynchronization Therapy. American Journal of Cardiology, 2012, 110, 398-402.	0.7	21
88	Quantitative assessment of a second-generation cryoballoon ablation catheter with new cooling technologyâ€"a perspective on potential implications on outcome. Journal of Interventional Cardiac Electrophysiology, 2014, 40, 17-21.	0.6	21
89	Effects of Diltiazem and Esmolol on Cycle Length and Spontaneous Conversion of Atrial Fibrillation. Journal of Cardiovascular Pharmacology and Therapeutics, 2002, 7, 81-88.	1.0	19
90	Effect of Implantable Cardioverter-Defibrillator on Left Ventricular Ejection Fraction in Patients With Idiopathic Dilated Cardiomyopathy. American Journal of Cardiology, 2010, 106, 1640-1645.	0.7	19

#	Article	IF	Citations
91	Cardiac resynchronization therapy pacemaker or cardiac resynchronization therapy defibrillator: what determines the choice?—findings from the ESC CRT Survey II. Europace, 2019, 21, 918-927.	0.7	19
92	Development and external validation of prediction models to predict implantable cardioverter-defibrillator efficacy in primary prevention of sudden cardiac death. Europace, 2021, 23, 887-897.	0.7	19
93	Effects of Verapamil and Ibutilide on Atrial Fibrillation and Postfibrillation Atrial Refractoriness. Journal of Cardiovascular Electrophysiology, 2002, 13, 151-157.	0.8	18
94	Cardiological diagnostic workâ€up in stroke patients – a comprehensive study of test results and therapeutic implications. European Journal of Neurology, 2009, 16, 268-273.	1.7	18
95	Rationale and design of the EUâ€CERTâ€ICD prospective study: comparative effectiveness of prophylactic ICD implantation. ESC Heart Failure, 2019, 6, 182-193.	1.4	18
96	Comparison of Verapamil and Ibutilide for the Suppression of Immediate Recurrences of Atrial Fibrillation after Transthoracic Cardioversion. Journal of Cardiovascular Pharmacology and Therapeutics, 2002, 7, 155-160.	1.0	17
97	Routine echocardiography after radiofrequency ablation: to flog a dead horse?. Europace, 2008, 11, 155-157.	0.7	17
98	Superior Vena Cava Stenosis after Radiofrequency Catheter Ablation for Electrical Isolation of the Superior Vena Cava. PACE - Pacing and Clinical Electrophysiology, 2010, 33, e36-e38.	0.5	17
99	The FIRE AND ICE Trial: What We Know, What We Can Still Learn, and What We Need to Address in the Future. Journal of the American Heart Association, 2018, 7, e010777.	1.6	17
100	Advanced ECG in 2016: is there more than just a tracing?. Swiss Medical Weekly, 2016, 146, w14303.	0.8	17
101	Fluoroscopy-Free Pulmonary Vein Isolation in Patients with Atrial Fibrillation and a Patent Foramen Ovale Using Solely an Electroanatomic Mapping System. PLoS ONE, 2016, 11, e0148059.	1.1	16
102	C-reactive protein for prediction of atrial fibrillation recurrence after catheter ablation. BMC Cardiovascular Disorders, 2020, 20, 427.	0.7	16
103	Association of Diabetes With Atrial Fibrillation Phenotype and Cardiac and Neurological Comorbidities: Insights From the Swissâ€AF Study. Journal of the American Heart Association, 2021, 10, e021800.	1.6	16
104	Leadless pacemaker implantation quality: importance of the operator's experience. Europace, 2020, 22, 939-946.	0.7	15
105	Role of Coronary Angiography Before Radiofrequency Ablation in Patients Presenting With Paroxysmal Supraventricular Tachycardia. Journal of Cardiovascular Pharmacology and Therapeutics, 2007, 12, 137-144.	1.0	14
106	Effective reduction of fluoroscopy duration by using an advanced electroanatomic-mapping system and a standardized procedural protocol for ablation of atrial fibrillation: 'the unleaded study'. Europace, 2015, 17, 1694-9.	0.7	14
107	QTc interval, cardiovascular events and mortality in patients with atrial fibrillation. International Journal of Cardiology, 2018, 252, 101-105.	0.8	14
108	Comparison of acute and long-term effects of single-dose amiodarone and verapamil for the treatment of immediate recurrences of atrial fibrillation after transthoracic cardioversion. Europace, 2005, 7, 546-553.	0.7	13

#	Article	IF	Citations
109	Thrombo-embolic occlusion of the left anterior descending coronary artery complicating left atrial radiofrequency ablation. Europace, 2008, 11, 117-118.	0.7	13
110	Holter Monitoring in Syncope: Diagnostic Yield in Octogenarians. Journal of the American Geriatrics Society, 2011, 59, 1293-1298.	1.3	13
111	Relationship Between Serum Potassium Concentration and Risk of Recurrent Ventricular Tachycardia or Ventricular Fibrillation. Journal of Cardiovascular Electrophysiology, 2001, 12, 1109-1112.	0.8	12
112	Optimization of imaging before pulmonary vein isolation by radiofrequency ablation: breath-held ungated versus ECG/breath-gated MRA. European Radiology, 2008, 18, 2879-2884.	2.3	12
113	Reduction of falls and fractures after permanent pacemaker implantation in elderly patients with sinus node dysfunction. Europace, 2017, 19, 1220-1226.	0.7	12
114	Canakinumab After Electrical Cardioversion in Patients With Persistent Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008197.	2.1	12
115	Technical and procedural comparison of two different cryoballoon ablation systems in patients with atrial fibrillation. Journal of Interventional Cardiac Electrophysiology, 2022, 64, 409-416.	0.6	12
116	Diagnostic value of single versus dual chamber electrograms recorded from an implantable defibrillator. Journal of Interventional Cardiac Electrophysiology, 2003, 9, 49-53.	0.6	11
117	Hypokalaemia and sudden cardiac death-lessons from implantable cardioverter defibrillators. Emergency Medicine Journal, 2007, 24, 206-208.	0.4	11
118	Conventional versus 3â€D Echocardiography to Predict Arrhythmia Recurrence After Atrial Fibrillation Ablation. Journal of Cardiovascular Electrophysiology, 2017, 28, 651-658.	0.8	11
119	Appropriate Shocks and Mortality in Patients With Versus Without Diabetes With Prophylactic Implantable Cardioverter Defibrillators. Diabetes Care, 2020, 43, 196-200.	4.3	11
120	Impact of contact force sensing technology on outcome of catheter ablation of idiopathic pre-mature ventricular contractions originating from the outflow tracts. Europace, 2021, 23, 603-609.	0.7	11
121	Prevalence and predictors of atrial fibrillation type among individuals with recent onset of atrial fibrillation. Swiss Medical Weekly, 2018, 148, w14652.	0.8	11
122	Efficacy and safety of a novel cryoballoon ablation system: multicentre comparison of 1-year outcome. Europace, 2022, 24, 1926-1932.	0.7	11
123	Incidence and Clinical Significance of Inducible Atrial Tachycardia in Patients with Atrioventricular Nodal Reentrant Tachycardia. Journal of Cardiovascular Electrophysiology, 2001, 12, 507-510.	0.8	10
124	Arrhythmogenic right ventricular dysplasia presenting as right ventricular outflow tract tachycardia. Europace, 2005, 7, 345-347.	0.7	10
125	High-sensitive cardiac troponin T as a predictor of efficacy and safety after pulmonary vein isolation using focal radiofrequency, multielectrode radiofrequency and cryoballoon ablation catheter. Open Heart, 2019, 6, e000949.	0.9	10
126	Management of conduction disorders after transcatheter aortic valve implantation: results of the EHRA survey. Europace, 2022, 24, 1179-1185.	0.7	10

#	Article	IF	CITATIONS
127	An Unusual Cause of ICD Shock. PACE - Pacing and Clinical Electrophysiology, 1997, 20, 2265-2267.	0.5	9
128	A randomized trial comparing two different approaches of pacemaker selection. Europace, 2007, 9, 1185-1190.	0.7	9
129	Characterization and financial impact of implantable cardioverter-defibrillator patients without interventions 5 years after implantation. QJM - Monthly Journal of the Association of Physicians, 2011, 104, 849-857.	0.2	9
130	Long-Term Prognostic Value of Restitution Slope in Patients with Ischemic and Dilated Cardiomyopathies. PLoS ONE, 2013, 8, e54768.	1.1	9
131	One-year follow-up after irrigated multi-electrode radiofrequency ablation of persistent atrial fibrillation. Europace, 2016, 18, 85-91.	0.7	9
132	Risk factors for heart failure hospitalizations among patients with atrial fibrillation. PLoS ONE, 2018, 13, e0191736.	1.1	9
133	Prevalence and Management of Atrial Thrombi in Patients With Atrial Fibrillation Before Pulmonary Vein Isolation. JACC: Clinical Electrophysiology, 2019, 5, 1406-1414.	1.3	9
134	Incidence and Predictors of Heart Failure in Patients With Atrial Fibrillation. CJC Open, 2021, 3, 1482-1489.	0.7	9
135	Uptake of non-vitamin K antagonist oral anti coagulants in patients with atrial fibrillation – a prospective cohort study. Swiss Medical Weekly, 2017, 147, w14410.	0.8	9
136	QRS micro-fragmentation as a mortality predictor. European Heart Journal, 2022, 43, 4177-4191.	1.0	9
137	Prophylactic implantable cardioverter defibrillator therapy in dilated cardiomyopathy: Impact of left ventricular function. International Journal of Cardiology, 2006, 108, 26-30.	0.8	8
138	Long-term performance of the Medtronic Sprint Fidelis lead: a matter of lead type?. Europace, 2012, 14, 1620-1623.	0.7	8
139	X-ray-free implantation of a permanent pacemaker during pregnancy using a 3D electro-anatomic mapping system. European Heart Journal, 2015, 36, 2790.1-2790.	1.0	8
140	Stateâ€ofâ€theâ€art multimodality approach to assist ablations in complex anatomiesâ€"From 3D printing to virtual reality. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 101-103.	0.5	8
141	Blood Pressure and Brain Lesions in Patients With Atrial Fibrillation. Hypertension, 2021, 77, 662-671.	1.3	8
142	Effect of atrial fibrillation duration on probability of immediate recurrence after transthoracic cardioversion. Journal of Cardiovascular Electrophysiology, 2003, 14, 182-5.	0.8	8
143	High-power short-duration ablation index–guided pulmonary vein isolation protocol using a single catheter. Journal of Interventional Cardiac Electrophysiology, 2022, 65, 633-642.	0.6	8
144	Application of a mortality risk score in a general population of patients with an implantable cardioverter defibrillator (ICD). Heart, 2014, 100, 487-491.	1.2	7

#	Article	IF	CITATIONS
145	Changing exits in ventricular outflow tract tachycardia. Heart Rhythm, 2014, 11, 1495-1496.	0.3	7
146	Reliability of luminal oesophageal temperature monitoring during radiofrequency ablation of atrial fibrillation: insights from probe visualization and oesophageal reconstruction using magnetic resonance imaging. Europace, 2017, 19, euw129.	0.7	7
147	Predicting defibrillator benefit in patients with cardiac resynchronization therapy: A competing risk study. Heart Rhythm, 2019, 16, 1057-1064.	0.3	7
148	Effect of COVID-19 on acute treatment of ST-segment elevation and Non-ST-segment elevation acute coronary syndrome in northwestern Switzerland. IJC Heart and Vasculature, 2021, 32, 100686.	0.6	7
149	Insulin-like growth factor-binding protein 7 and risk of congestive heart failure hospitalization in patients with atrial fibrillation. Heart Rhythm, 2021, 18, 512-519.	0.3	7
150	Cardiac resynchronization therapy in chronic heart failure. Swiss Medical Weekly, 2006, 136, 611-7.	0.8	7
151	Ventricular tachycardia in an ice-hockey player after a blunt chest trauma. International Journal of Cardiology, 2007, 114, 378-379.	0.8	6
152	Effects of physical exercise on cardiac dyssynchrony in patients with impaired left ventricular function. Europace, 2011, 13, 839-844.	0.7	6
153	Fluoroscopy-free recrossing of the interatrial septum during left atrial ablation procedures. Journal of Interventional Cardiac Electrophysiology, 2014, 41, 261-266.	0.6	6
154	Repetitive inappropriate implantable cardioverter-defibrillator shocks due to insulation failure with externalized conductor cables of a Biotronik Linox SD ICD lead. Europace, 2016, 18, 686-686.	0.7	6
155	Electroanatomic mapping of atrial tachycardiaâ€"Manual vs automated annotation. HeartRhythm Case Reports, 2017, 3, 145-147.	0.2	6
156	Comparison of Multivariate Risk Estimation Models to Predict Prognosis in Patients With Implantable Cardioverter Defibrillators With or Without Cardiac Resynchronization Therapy. American Journal of Cardiology, 2017, 119, 1414-1420.	0.7	6
157	Ablation of typical atrial flutter guided by the paced PR interval on the surface electrocardiogram: a proof of concept study. Europace, 2019, 21, 1750-1754.	0.7	6
158	ECG-Based Indices to Characterize Persistent Atrial Fibrillation Before and During Stepwise Catheter Ablation. Frontiers in Physiology, 2021, 12, 654053.	1.3	6
159	Transcatheter renal denervation for the treatment of resistant arterial hypertension: the Swiss expert consensus. Swiss Medical Weekly, 2014, 144, w13913.	0.8	6
160	Prevalence of severely impaired left ventricular ejection fraction after reperfused ST-elevation myocardial infarction. Swiss Medical Weekly, 2013, 143, w13869.	0.8	6
161	Use of the wearable cardioverter-defibrillator – the Swiss experience. Swiss Medical Weekly, 2020, 150, w20343.	0.8	6
162	What are the professional and logistic demands to appropriately follow patients with an implantable cardioverter-defibrillator?. Journal of Internal Medicine, 2006, 260, 88-92.	2.7	5

#	Article	IF	CITATIONS
163	Wolff-Parkinson-White Syndrome and Atrial Fibrillation in a Patient With a Coronary Sinus Diverticulum. Circulation, 2007, 115, e469-71.	1.6	5
164	Electrical Storm Caused by Complementary Medication with Ginkgo Biloba Extract. American Journal of Medicine, 2008, 121, e3-e4.	0.6	5
165	Comparison of Different Approaches to Atrioventricular Junction Ablation and Pacemaker Implantation in Patients with Atrial Fibrillation. PACE - Pacing and Clinical Electrophysiology, 2014, 37, 1686-1693.	0.5	5
166	Determinants of Left Atrial Volume in Patients with Atrial Fibrillation. PLoS ONE, 2016, 11, e0164145.	1.1	5
167	A quantitative comparison of the electrical and anatomical definition of the pulmonary vein ostium. PACE - Pacing and Clinical Electrophysiology, 2017, 40, 1213-1217.	0.5	5
168	Right VErsus Left Apical transvenous pacing for bradycardia: Results of the RIVELA randomized study. Indian Pacing and Electrophysiology Journal, 2017, 17, 171-175.	0.3	5
169	Case report: electrical storm during induced hypothermia in a patient with early repolarization. BMC Cardiovascular Disorders, 2017, 17, 277.	0.7	5
170	Reassessment of cardiovascular parameters and comorbidities in implantable cardioverterâ€defibrillator patients at the time of first replacement. Clinical Cardiology, 2018, 41, 57-62.	0.7	5
171	Burden-based classification of atrial fibrillation predicts multiple-procedure success of pulmonary vein isolation. Journal of Cardiology, 2019, 74, 53-59.	0.8	5
172	First-degree atrioventricular block in patients with atrial fibrillation and atrial flutter: the prevalence of intra-atrial conduction delay. Journal of Interventional Cardiac Electrophysiology, 2021, 61, 421-425.	0.6	5
173	Association of psychosocial factors with all ause hospitalizations in patients with atrial fibrillation. Clinical Cardiology, 2021, 44, 51-57.	0.7	5
174	Q waves are the strongest electrocardiographic variable associated with primary prophylactic implantable cardioverter-defibrillator benefit: a prospective multicentre study. Europace, 2022, 24, 774-783.	0.7	5
175	Cryoballoon Ablation of Atrial Fibrillation Without Demonstration of Pulmonary Vein Occlusionâ€"The Simplify Cryo Study. Frontiers in Cardiovascular Medicine, 2021, 8, 664538.	1.1	5
176	Application of the heart failure meta-score to predict prognosis in patients with cardiac resynchronization defibrillators. International Journal of Cardiology, 2021, 330, 73-79.	0.8	5
177	Clinical validation of a novel smartwatch for automated detection of atrial fibrillation. Heart Rhythm O2, 2022, 3, 208-210.	0.6	5
178	Long-term risk of adverse outcomes according to atrial fibrillation type. Scientific Reports, 2022, 12, 2208.	1.6	5
179	Magnetic Field Measurements of Portable Electronic Devices: The Risk Inside Pockets for Patients With Cardiovascular Implantable Devices. Circulation: Arrhythmia and Electrophysiology, 2022, 15, CIRCEP121010646.	2.1	5
180	A Long RP Tachycardia: What is the Tachycardia Mechanism?. Journal of Cardiovascular Electrophysiology, 2001, 12, 115-117.	0.8	4

#	Article	IF	CITATIONS
181	Impact of left ventricular ejection fraction on occurrence of ventricular events in defibrillator patients with coronary artery disease. Europace, 2011, 13, 1562-1567.	0.7	4
182	A Plea for Delivery of High-Voltage Shocks During Implantable Cardioverter-Defibrillator Replacement or System Upgrade. Canadian Journal of Cardiology, 2012, 28, 611.e5-611.e6.	0.8	4
183	Paroxysmal atrial fibrillation recurrence after redo procedure-ablation modality impact. Journal of Interventional Cardiac Electrophysiology, 2020, 57, 77-85.	0.6	4
184	Symptoms and quality of life in patients with coexistent atrial fibrillation and atrial flutter. IJC Heart and Vasculature, 2020, 29, 100556.	0.6	4
185	Electrocardiogram as a predictor of survival without appropriate shocks in primary prophylactic ICD patients: A retrospective multi-center study. International Journal of Cardiology, 2020, 309, 78-83.	0.8	4
186	Cryoballoon pulmonary vein isolation as first line treatment for typical atrial flutter (CRAFT): study protocol for a randomised controlled trial. Journal of Interventional Cardiac Electrophysiology, 2021, 60, 427-432.	0.6	4
187	Alcohol consumption and risk of cardiovascular outcomes and bleeding in patients with established atrial fibrillation. Cmaj, 2021, 193, E117-E123.	0.9	4
188	Swiss National Registry on Catheter Ablation Procedures: Changing Trends over the Last 20 Years. Journal of Clinical Medicine, 2021, 10, 3021.	1.0	4
189	Prospective Evaluation of a Standardized Screening for Atrial Fibrillation after Ablation of Cavotricuspid Isthmus Dependent Atrial Flutter. Journal of Clinical Medicine, 2021, 10, 4453.	1.0	4
190	Persistent improvement of ejection fraction in patients with a cardiac resynchronisation therapy defibrillator correlates with fewer appropriate ICD interventions and lower mortality. Swiss Medical Weekly, 2016, 146, w14300.	0.8	4
191	Noninvasive Monitoring of Stroke Volume With Resynchronization Devices in Patients With Ischemic Cardiomyopathy. Journal of Cardiac Failure, 2013, 19, 577-582.	0.7	3
192	Man vs machine: Performance of manual vs automated electrocardiogram analysis for predicting the chamber of origin of idiopathic ventricular arrhythmia. Journal of Cardiovascular Electrophysiology, 2020, 31, 410-416.	0.8	3
193	Severe and uniform bi-atrial remodeling measured by dominant frequency analysis in persistent atrial fibrillation unresponsive to ablation. Journal of Interventional Cardiac Electrophysiology, 2020, 59, 431-440.	0.6	3
194	The Admit-AF risk score: A clinical risk score for predicting hospital admissions in patients with atrial fibrillation. European Journal of Preventive Cardiology, 2021, 28, 624-630.	0.8	3
195	Nocturnal respiratory rate predicts ICD benefit: A prospective, controlled, multicentre cohort study. EClinicalMedicine, 2021, 31, 100695.	3.2	3
196	Automated electrocardiographic quantification of myocardial scar in patients undergoing primary prevention implantable cardioverter-defibrillator implantation: Association with mortality and subsequent appropriate and inappropriate therapies. Heart Rhythm, 2020, 17, 1664-1671.	0.3	3
197	Sex-specific differences in adverse outcome events among patients with atrial fibrillation. Heart, 2022, 108, 1445-1451.	1.2	3
198	A machine learning algorithm for electrocardiographic fQRS quantification validated on multi-center data. Scientific Reports, 2022, 12, 6783.	1.6	3

#	Article	IF	Citations
199	Unique interaction between an atrial single-chamber pacemaker and a ventricular defibrillator. Journal of Interventional Cardiac Electrophysiology, 2000, 4, 241-244.	0.6	2
200	Cost Analysis of Transthoracic Cardioversion of Atrial Fibrillation With and Without Ibutilide Pretreatment. Journal of Cardiovascular Pharmacology and Therapeutics, 2000, 5, 259-266.	1.0	2
201	A Delta Wave in a Healthy Swiss Conscript: One Does Not Always Have to Burn to Learn. PACE - Pacing and Clinical Electrophysiology, 2010, 33, e93-e95.	0.5	2
202	Entering through the back-door: remotely navigated ablation of left atrial tachycardia in the presence of a large atrial septal defect occluder. Europace, 2013, 15, 943-943.	0.7	2
203	Fluoroscopyâ€Free PVI With nMARQ TM in a Patient With a PFO. Journal of Cardiovascular Electrophysiology, 2015, 26, 906-906.	0.8	2
204	Very Late Followâ€Up of a Passive Defibrillator Lead Under Recall: Do Failure Rates Increase during Longâ€Term Observation. PACE - Pacing and Clinical Electrophysiology, 2015, 38, 306-310.	0.5	2
205	First clinical experience of a dedicated irrigated-tip radiofrequency ablation catheter for the ablation of cavotricuspid isthmus-dependent atrial flutter. Clinical Research in Cardiology, 2018, 107, 281-286.	1.5	2
206	Comment to: Reduction in mortality from implantable cardioverter-defibrillators in non-ischaemic cardiomyopathy patients is dependent on the presence of left ventricular scar. European Heart Journal, 2019, 40, 2996-2996.	1.0	2
207	The Medtronic Sprint Fidelis® lead history revisitedâ€"Extended followâ€up of passive leads. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 1529-1533.	0.5	2
208	Predicting Early Mortality Among Implantable Defibrillator Patients Treated With Cardiac Resynchronization Therapy. Journal of Cardiac Failure, 2019, 25, 812-818.	0.7	2
209	Surgical repair of an esophageal perforation after radiofrequency catheter ablation for atrial fibrillation. Indian Pacing and Electrophysiology Journal, 2019, 19, 110-113.	0.3	2
210	Epicardial Connection. JACC: Clinical Electrophysiology, 2019, 5, 1356-1357.	1.3	2
211	Reassessment of clinical variables in cardiac resynchronization defibrillator patients at the time of first replacement:ÂDeath after replacement of CRT (DARC) score. Journal of Cardiovascular Electrophysiology, 2021, 32, 1687-1694.	0.8	2
212	Association of Heart Rate Variability With Silent Brain Infarcts in Patients With Atrial Fibrillation. Frontiers in Cardiovascular Medicine, 2021, 8, 684461.	1.1	2
213	A Simplified Method to Detect Phrenic Nerve Injury During Cryoballoon Ablation of Atrial Fibrillation Using Lead aVF of the Surface ECG. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e009986.	2.1	2
214	Outcome of patients with dilated cardiomyopathy in a contemporary Swiss population. Acta Cardiologica, 2009, 64, 347-350.	0.3	2
215	Noninvasive Diagnosis of a Wide QRS Complex Tachycardia Mechanism by Programmed Atrial and Ventricular Stimulation Using a Dual Chamber Defibrillator. PACE - Pacing and Clinical Electrophysiology, 2001, 24, 1097-1099.	0.5	1
216	An unusual cause of cardiogenic shock. European Heart Journal, 2010, 31, 1632-1632.	1.0	1

#	Article	IF	CITATIONS
217	Remotely Monitored Death of a Patient with Implanted ICD. PACE - Pacing and Clinical Electrophysiology, 2012, 35, e280-3.	0.5	1
218	Isolation of an Automatic Purkinje Focus for Ablation of an Incessant Ventricular Tachycardia. Circulation: Arrhythmia and Electrophysiology, 2014, 7, 1275-1276.	2.1	1
219	Slow automaticity of a Mahaim fibre after radiofrequency ablation. Europace, 2014, 16, 1705-1705.	0.7	1
220	Cryoballoon ablation for atrial fibrillation. Interventional Cardiology, 2014, 6, 373-382.	0.0	1
221	Atrial electrogram quality in single-pass defibrillator leads with floating atrial bipole in patients with permanent atrial fibrillation and cardiac resynchronization therapy. Indian Pacing and Electrophysiology Journal, 2018, 18, 140-145.	0.3	1
222	Present criteria for prophylactic ICD implantation: Insights from the EU-CERT-ICD (Comparative) Tj ETQq0 0 0 rgB	T /Overloc 0.4	k 10 Tf 50 5 1
223	High Incidence of Inappropriate Alarms in Patients with Wearable Cardioverter-Defibrillators: Findings from the Swiss WCD Registry. Journal of Clinical Medicine, 2021, 10, 3811.	1.0	1
224	Cryoballoon ablation: The pure and simple truth about the left common ostium?. Heart Rhythm, 2017, 14, 1119-1120.	0.3	1
225	Outcome of patients with cardiac resynchronisation defibrillator therapy and a follow-up of at least five years after implant. Swiss Medical Weekly, 2014, 144, w13938.	0.8	1
226	A rare and reversible cause of third-degree atrioventricular block: a case report. European Heart Journal - Case Reports, 2021, 5, ytab372.	0.3	1
227	Changes in renal function over time in patients with cardiac resynchronisation therapy. Swiss Medical Weekly, 2013, 143, w13863.	0.8	1
228	Cardiac Resynchronisation Therapy (CRT) Survey II: CRT implantation in Europe and in Switzerland. Swiss Medical Weekly, 2018, 148, w14643.	0.8	1
229	Predictors for early mortality and arrhythmic events in patients with cardiac resynchronization therapy with defibrillator: A two center cohort study. Cardiology Journal, 2020, 26, 711-716.	0.5	1
230	Treating Atrial Fibrillation With Cryoballoon Technology. Journal of Atrial Fibrillation, 2012, 4, 486.	0.5	1
231	Association of pulmonary vein isolation and major cardiovascular events in patients with atrial fibrillation. Clinical Research in Cardiology, 2022, , 1.	1.5	1
232	Nonâ€invasive evaluation of newâ€onset atrial fibrillation after cardiac surgery: a protocol for the BigMap study. ESC Heart Failure, 2022, , .	1.4	1
233	Transient cortical blindness after coronary angiography. Lancet, The, 1998, 351, 1514.	6.3	0
234	Addendum to: Trypanosoma brucei tryparedoxin, a thioredoxin-like protein in African trypanosomes (FEBS 20556). FEBS Letters, 1998, 437, 165-165.	1.3	0

#	Article	IF	CITATIONS
235	Response to Letter Regarding Article, "Death Without Prior Appropriate Implantable Cardioverter-Defibrillator Therapy: A Competing Risk Study― Circulation, 2008, 118, .	1.6	O
236	Implantation of a CRT Device., 0,, 156-179.		0
237	Response to Letter Regarding Article, "Necessity for Surgical Revision of Chronically Implanted Defibrillator Leads: Causes and Management― Circulation, 2009, 119, .	1.6	O
238	No Benefit From Cardiac Resynchronization Therapy in Asymptomatic Patients. Journal of the American College of Cardiology, 2009, 53, 2198.	1.2	0
239	Expecting the unpredictable. Heart Rhythm, 2012, 9, 721-722.	0.3	O
240	Retrograde placement of a defibrillator lead through the pulmonary valve. Heart Rhythm, 2012, 9, 315-316.	0.3	0
241	Interplay between Arrhythmias Originating in the Right Ventricular Outflow Tract and the Left Coronary Cusp. PACE - Pacing and Clinical Electrophysiology, 2012, 35, e356-7.	0.5	0
242	Ebstein's Anomaly Unmasked by Accessory Pathway Ablation. Journal of Cardiovascular Electrophysiology, 2014, 25, 1261-1262.	0.8	0
243	Concurrent Cardioversion of Atrial Fibrillation during ICD Shock Testing. PACE - Pacing and Clinical Electrophysiology, 2015, 38, 864-869.	0.5	0
244	Pulmonary vein isolation: Is our target the one we think?. Heart Rhythm, 2016, 13, 1858-1859.	0.3	0
245	Pulmonary vein isolation without assessing pulmonary vein potentials: Not there yet. Heart Rhythm, 2017, 14, 329-330.	0.3	0
246	Wide and narrow QRS complex tachycardia with four different cycle lengths: What is the mechanism?. Heart Rhythm, 2018, 15, 1736-1738.	0.3	0
247	Gadolinium based contrast agent-free cardiac magnetic resonance imaging for the assessment of heart anatomy. A feasibility study. Revista Espanola De Cardiologia (English Ed), 2020, 73, 510-512.	0.4	0
248	Ventricular tachycardia catheter ablation after repaired tetralogy of Fallot: how to overcome an electrical short circuit. Europace, 2020, 22, 1687-1687.	0.7	0
249	Wearable cardioverter-defibrillator in patients at risk of sudden cardiac death: consensus document from Kalarus et al. contradicts current guideline recommendations—Authors' reply. Europace, 2020, 22, 1442-1443.	0.7	0
250	Wearable cardioverter-defibrillator to reduce the transient risk of sudden cardiac death in coronary artery disease: Authors' reply. Europace, 2020, 22, 1600-1601.	0.7	0
251	Defibrillators for prevention from sudden cardiac death: is it that easy?—Authors' reply. Europace, 2020, 22, 1298-1299.	0.7	0
252	Substrate characterization for ventricular tachycardia ablation using a new image processing service. Clinical Research in Cardiology, 2021, 110, 913-915.	1.5	0

#	Article	IF	CITATIONS
253	Preâ€procedural arrhythmia burden and the outcome of catheter ablation of idiopathic premature ventricular complexes. PACE - Pacing and Clinical Electrophysiology, 2021, 44, 703-710.	0.5	0
254	Non-invasive predictors for infranodal conduction delay in patients with left bundle branch block after TAVR. Clinical Research in Cardiology, 2021, 110, 1967-1976.	1.5	0
255	Dynamics of Intraprocedural Dominant Frequency Identifies Ablation Outcome in Persistent Atrial Fibrillation. Frontiers in Physiology, 2021, 12, 731917.	1.3	0
256	Prediction of Atrial Fibrillation Termination by Catheter Ablation Using Adaptive Frequency Tracking of Atrial ECG Signals. , 0, , .		0
257	OUP accepted manuscript. European Heart Journal, 2020, 41, 724.	1.0	O
258	High-sensitivity cardiac Troponin T delta concentration after repeat pulmonary vein isolation. Biochemia Medica, 2019, 29, 407-412.	1.2	0
259	lmágenes de resonancia magnética cardiaca sin contraste basadas en gadolinio para la evaluación de la anatomÃa del corazón: un estudio de viabilidad. Revista Espanola De Cardiologia, 2020, 73, 510-512.	0.6	0
260	Arrhythmic Risk in Male and Female Patients With Heart Failureâ€"Same but Different. JAMA Network Open, 2022, 5, e2217167.	2.8	0